The CIGNA Health Awareness Tour Mobile Learning Lab is an experiential exhibit on 18 wheels that helps to raise awareness and understanding of traditional and non-traditional influencers of health.
Many health awareness efforts seek to increase individual understanding of the importance of key “numbers” or medical indicators of health, such as blood pressure and cholesterol levels. While these measures are important, the Mobile Learning Lab takes awareness to a new level, challenging guests to look at health more holistically.
To view Multimedia News Release, go to http://www.multivu.com/players/English/46644-CIGNA-Mobile-Learning-Lab/
Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, will showcase its 3D mammography and other new, ready-to-market technologies in women’s imaging at the 21st Annual National Interdisciplinary Breast Center Conference (NCBC) in Las Vegas, Nevada, March 12-16, 2011. The NCBC is a nonprofit membership organization dedicated to excellence in breast healthcare for the general public.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/hologic/39364/
Two of the most advanced tools for precise, radiotherapy-based treatment are now under one roof in Seattle. Swedish Medical Center this month became the first facility in the Pacific Northwest – and one of only a handful in North America – to open a unit that incorporates both CyberKnife and Gamma Knife technologies. The 3,950-square-foot Swedish Radiosurgery Center, formerly known as the Seattle CyberKnife Center, is located on the
Baylor University Medical Center at Dallas (Baylor Dallas) is now home to North Texas’ largest outpatient cancer center. The new Baylor Charles A. Sammons Cancer Center at Dallas opens to the public Saturday, March 26. The 467,000 square-foot facility marks a new era in cancer care for the Dallas-Fort Worth Metroplex and beyond by offering comprehensive services for cancer patients from initial diagnosis through post-recovery. Baylor Dallas, already the leading cancer care provider in North Texas in terms of patients treated and according to Consumer Choice data, now brings together multiple phases of cancer care under one roof.
To view Multimedia news Release, go to http://multivu.prnewswire.com/mnr/baylorhealth/47429/
The new BUENA SALUD™ series of books (the phrase translates to “Good Health”) launches today with titles on heart health (foreword by CEO of the American College of Cardiology) and diabetes (foreword by CEO of the American Diabetes Association). Written by Dr. Jane L. Delgado, President and CEO of the National Alliance for Hispanic Health, the book series is the first ever devoted to the health experiences of a growing Hispanic readership. The guides feature real-life stories and deliver health information and cutting-edge medical advances for individual diseases and conditions in a warm and conversational tone. The books are published simultaneously in English and Spanish. These authoritative and accessible guides each feature a “10-Point Program for Health,” facts and information in a useful Q&A format, and key questions to ask health providers. In a just published feature review, the Library Journal gave a starred review and called the BUENA SALUD™ series “essential reading” and “a crucial addition to any consumer health collection.”
Carnival Cruise Lines hosted a first-ever post-race wedding ceremony at the 2011 Cooper River Bridge Run this weekend, the culminating event in the Race to the Altar contest and fundraiser which resulted in a $10,000 donation to the Medical University of South Carolina (MUSC) Children’s Hospital.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/carnival/49452/
The Department of Veterans Affairs (VA) is celebrating exceptional care for Veterans this week, May 2 – 6 as part of the nationally recognized Research Week. This year’s theme, “Discovery and Collaboration for Exceptional Health Care,” celebrates two crucial elements of VA research: dedicated follow-through on important research findings to optimize medical therapies for Veterans and others; and vital research and care collaborations between VA and academic institutions, other government agencies, and health-related industry.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/va/48428/
According to a new report, How Can We Avoid a Stroke Crisis in the Asia-Pacific Region?, urgent coordinated action is needed to avoid millions of preventable strokes, which leave many patients who have atrial fibrillation (AF) both mentally and physically disabled, or dead, every year.
The report, launched today during the 18th Asian Pacific Congress of Cardiology (APCC) by Action for Stroke Prevention, a group of health experts from across the globe, proposes urgent measures to prevent stroke in Asia-Pacific patients with AF, the most common, sustained abnormal heart rhythm and a major cause of stroke. The report’s recommendations are endorsed by 32 leading Asia-Pacific and other global medical societies and patient organizations, reinforcing and recognizing the need for a call to action.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/strikeoutstroke/48909/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
Thirty-six million Americans suffer from migraines, leading to more than $20 billion in medical expenses and costs related to lost productivity each year¹. In recognition of National Migraine Awareness Month and the significant unmet medical needs of migraine patients, Zogenix, Inc. (NASDAQ: ZGNX) is highlighting the importance of selecting the appropriate medication for a patient’s “treatment toolbox” to address specific types of migraine episodes.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/zogenix/50344/
Presented here are few of the products which Vertex Product Development has designed, engineered and developed from conception to production for the Consumer, Commercial, Industrial and Medical industries.
Presented here are few of the products which Vertex Product Development has designed, engineered and developed from conception to production for the Consumer, Commercial, Industrial and Medical industries.
